<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18905">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860780</url>
  </required_header>
  <id_info>
    <org_study_id>16379</org_study_id>
    <secondary_id>I4D-MC-JTJL</secondary_id>
    <secondary_id>2015-005611-33</secondary_id>
    <nct_id>NCT02860780</nct_id>
  </id_info>
  <brief_title>A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug prexasertib in
      combination with ralimetinib in participants with advanced or metastatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Prexasertib and Ralimetinib</measure>
    <time_frame>Cycle 1 (28 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Prexasertib</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 3 Day 1 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Curve (AUC) of Prexasertib</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of Ralimetinib</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Ralimetinib</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR): Percentage of Participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE)</measure>
    <time_frame>Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Estimated up to 32 Weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants who Exhibit SD, CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 32 Weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 32 Weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated Up to 32 Weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: prexasertib + ralimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prexasertib given intravenously (IV) and ralimetinib given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B1: prexasertib + ralimetinib (colorectal cancer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prexasertib given IV and ralimetinib given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B2: prexasertib + ralimetinib (NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prexasertib given IV and ralimetinib given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prexasertib</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Part A: prexasertib + ralimetinib</arm_group_label>
    <arm_group_label>Part B1: prexasertib + ralimetinib (colorectal cancer)</arm_group_label>
    <arm_group_label>Part B2: prexasertib + ralimetinib (NSCLC)</arm_group_label>
    <other_name>LY2606368</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ralimetinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: prexasertib + ralimetinib</arm_group_label>
    <arm_group_label>Part B1: prexasertib + ralimetinib (colorectal cancer)</arm_group_label>
    <arm_group_label>Part B2: prexasertib + ralimetinib (NSCLC)</arm_group_label>
    <other_name>LY2228820</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or metastatic cancer.

          -  Able to swallow tablets.

          -  For Part B, you will need to have colon cancer or non-small cell lung (NSCLC) cancer
             with KRAS and/or BRAF mutations.

          -  Discontinued all previous treatments for cancer and recovered from the acute effects
             from the therapy.

        Exclusion Criteria:

          -  Active infection (fungal, viral, or bacterial).

          -  Active cancer in your brain or spinal cord.

          -  Acute or chronic leukemia.

          -  Serious heart condition.

          -  Disease that requires immunosuppressant therapy.

          -  Diagnosis of inflammatory bowel disease.

          -  Major small bowel resection that interferes with your body's ability to absorb the
             oral medicine.

          -  Participated in other clinical trials investigating prexasertib or ralimetinib.

          -  Pregnant or breastfeeding.

          -  Other pre-existing conditions or medical history which your doctor will explain to
             you.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>941-377-9993</phone>
    </contact>
    <investigator>
      <last_name>Judy Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institue</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>561-366-4112</phone>
    </contact>
    <investigator>
      <last_name>Shachar Peles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>980-442-2000</phone>
    </contact>
    <investigator>
      <last_name>Jimmy Hwang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7615</phone>
    </contact>
    <investigator>
      <last_name>SMO Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johanna Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/solid-tumor/JTJL#?postal=</url>
    <description>Click here for more information about this study: A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>August 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
